Clinical Trials

Showing trials with last updates posted in 2025.

NCT03801434 | RECRUITING | PHASE2
10 participants

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Study Type:
INTERVENTIONAL
Last Updated:
2025-12-23
Start Date:
2019-11-15
Completion:
2028-12-30
Conditions
  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression
Interventions
  • DRUG
No Results Yet
NCT03600233 | ACTIVE_NOT_RECRUITING | PHASE2
34 participants

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2025-12-23
Start Date:
2018-12-15
Completion:
2024-09-30
Conditions
  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumor
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Neoplasm
  • Neuroendocrine Carcinoma
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page